Pilot RCT of rapamycin with cardiac rehabilitation in older CAD patients shows design only, no results reported
This is a two-phase study protocol: phase 1 is a dose-escalation pilot in 18 older adults (≥60 years) with coronary artery disease undergoing cardiac rehabilitation, receiving oral rapamycin at 0.5, 1, or 2mg daily with measurement of frailty, quality of life, and senescent biomarkers; phase 2 is a planned RCT comparing exercise alone versus exercise plus low-dose rapamycin. No results are reported here—this is a protocol describing the planned intervention and endpoints.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 7, 2016 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients aged 60 years or older with coronary artery disease undergoing percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), or eligible to participate in cardiac rehabilitation
- Primary outcome
- Frailty (age-associated impairment); Phase 2 also tests measures of age-associated impairment (AAI) and senescent-associated secretory phenotype (SASP)
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Dec 7, 2016
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.